Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ia bukan cadangan pelaburan.
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.
Soalan Lazim
Apakah simbol saham E-Therapeutics?▼
Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa Boerse Stuttgart, saham E-Therapeutics didagangkan di bawah simbol 3AQ.STU.
Berapa ramai pekerja yang dimiliki oleh E-Therapeutics?▼
Sehingga 2 November 2026, syarikat mempunyai 34 pekerja.
E-Therapeutics terletak dalam sektor apa?▼
E-Therapeutics beroperasi dalam sektor Kesihatan & Kesejahteraan.
Bilakah E-Therapeutics menyiapkan split saham?▼
E-Therapeutics tidak mempunyai sebarang split baru-baru ini.
Di manakah ibu pejabat E-Therapeutics?▼
Ibu pejabat E-Therapeutics terletak di London, United Kingdom.